Three-dimensional direct neuronal reprogramming for modeling Alzheimer’s disease neuropathology
Abstract
This protocol presents a method for converting fibroblasts from patients with Alzheimer’s disease (AD) into cortical neurons, enabling the investigation of the molecular events underpinning AD-associated neurodegeneration and therapeutic testing. Patient fibroblasts are directly reprogrammed into cortical neurons grown as 3D thin‑gel cultures or self‑assembled spheroids, enabling rapid development of Alzheimer’s‑like Aβ deposition, tau dysregulation and neuronal loss. This system models age‑related Alzheimer’s pathology within weeks, providing a physiologically relevant, age-maintained, patient‑specific platform for studying disease mechanisms and testing therapeutic targets compared to other cell conversion approaches. Late-onset Alzheimer’s disease (LOAD) accounts for over 95% of Alzheimer’s disease (AD) cases. However, modeling the age-dependent neuropathological hallmarks of LOAD has remained a major challenge. We recently developed a patient-based, three-dimensional (3D) neuronal culture system that endogenously recapitulates key neuropathological features of AD, including extracellular Aβ deposition, tau dysregulation and spontaneous neuronal death. This platform uses high-efficiency, microRNA- and chromatin-based direct somatic reprogramming of fibroblasts from patients with autosomal dominant AD or LOAD to cortical neurons in 3D thin gel (3D-CNs) or self-assembled neuronal spheroids. Here we provide stepwise instructions for generating 3D-CNs and cortical spheroids via neuronal reprogramming of patient fibroblasts, along with methods for analyzing downstream AD neuropathology. Within 3 weeks, fibroblasts are reprogrammed into neurons under either thin-gel or spheroid conditions. By 4 weeks, key AD neuropathology, such as Aβ deposition, tau dysregulation, and neuronal death, can be detected in AD neurons. This system provides an age-relevant, patient-specific neuronal model for investigating molecular events underlying AD-associated neurodegeneration and evaluating compounds or gene targets in the context of potential personalized therapeutic interventions. Successful implementation of this protocol requires prior experience in mammalian cell culture, plasmid preparation, lentiviral production and standard confocal imaging techniques.